Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)

NCT02144077 is registered in ClinicalTrials.gov with Biofrontera Bioscience GmbH as lead sponsor.

NCT NCT02144077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02144077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)
Lead sponsor
Biofrontera Bioscience GmbH
Phase
Phase 3
Overall status
Completed
Start date
January 28, 2014
Completion date
September 9, 2020
Enrollment
281 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma (bcc)